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Abstract
RNA interference (RNAi) technology has not only become a powerful tool for functional genomics, but also allows
rapid drug target discovery and in vitro validation of these targets in cell culture. Furthermore, RNAi represents a
promising novel therapeutic option for treating human diseases, in particular cancer. Selective gene silencing by
RNAi can be achieved essentially by two nucleic acid based methods: i) cytoplasmic delivery of short double-
stranded (ds) interfering RNA oligonucleotides (siRNA), where the gene silencing effect is only transient in nature,
and possibly not suitable for all applications; or ii) nuclear delivery of gene expression cassettes that express short
hairpin RNA (shRNA), which are processed like endogenous interfering RNA and lead to stable gene down-
regulation. Both processes involve the use of nucleic acid based drugs, which are highly charged and do not cross
cell membranes by free diffusion. Therefore, in vivo delivery of RNAi therapeutics must use technology that enables
the RNAi therapeutic to traverse biological membrane barriers in vivo. Viruses and the vectors derived from them
carry out precisely this task and have become a major delivery system for shRNA. Here, we summarize and
compare different currently used viral delivery systems, give examples of in vivo applications, and indicate trends
for new developments, such as replicating viruses for shRNA delivery to cancer cells.
Introduction
The human genome project not only unraveled the
human genetic code, but spin-off technical improve-
ments also inspired genome sequencing of a multitude
of other organisms. However, since sequence data alone
are not sufficient to identify gene function, gene knock-
out or knock-in strategies have to replenish the results
in order to analyze the resulting phenotypic changes
defining gene functions.
Knowledge about the in vivo phenotype after knocking
out gene products is a prerequisite to assess the thera-
peutic potential of inhibitors against specific targets, so
in drug development knock-out animal models have
become very important. However, generating transgenic
animals is still very labor and cost intense. Alternatively,
selective silencing can be achieved by exploiting the
RNA interference (RNAi) machinery of the host cell.
Since its discovery by Fire and Mello [1] in C. elegans
in 1998, which gained them the Nobel prize in 2006,
and by Tuschl et al. [2] in mammalian cells in 2001,
RNAi was quickly adopted by the research community
as a versatile tool with a wide range of applications,
from reverse genetics to high throughput screening of
drug targets. The key therapeutic advantage of using
RNAi lies in its ability to specifically and potently
knock-down the expression of disease-causing genes of
known sequence.
Although RNAi is in comparison to knock-out strate-
gies, able to only knock-down the gene expression, sim-
ple in vivo inhibition of single gene products by RNAi
yields phenotypes that are comparable to classical
knock-out animals used for therapeutic target identifica-
tion or validation. Furthermore, basic research benefits
from in vivo RNAi as this strategy can be changed
dependent on the desired outcome. For example, condi-
tional gene knock-outs utilizing inducible promoters can
be used to unravel molecular pathways and investigate
functional genomics.
RNAi is a basic pathway in eukaryotic cells. In contrast
to activating cascades in cells upon exposure to long dou-
ble stranded RNA, leading to non-specific RNA degrada-
tion, RNAi is mediated by short RNA duplexes
hitchhiking a cellular pathway that silences genes in a
sequence-specific manner at the mRNA level. Perfectly
complementary dsRNA (short hairpin RNA, shRNA) is
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family member, into small interfering RNA (siRNA)
duplexes 21-23 nt in length with symmetric 2-3 nucleo-
tide (nt) 3’ overhangs [3]. The use of siRNA duplexes is
often accompanied by off-target effects, which can be
avoided or reduced by adding backbone modifications to
the duplexes to alter key thermodynamic and binding
properties [4-7]. DICER-chopped duplexes are incorpo-
rated into a protein complex called the RNA-induced
silencing complex (RISC) and subsequently unwound by
the multi-functional protein Argonaut 2, contained
within RISC. The activated RISC, which contains the
antisense strand (or guide strand) of the siRNA, is then
thought to direct the siRNA to the target mRNA with
identical sequence. This leads to degradation of the target
mRNA. The activated RISC complex can then move on
to destroy additional mRNA targets, which further pro-
pagates gene silencing [8,9]. This feature of the RNAi
mechanism induced by synthetic siRNA provides a
knock-down effect for up to seven days in rapidly divid-
ing cells and for several weeks in resting cells [10,11].
Thus, RNAi provides a simple, inexpensive and selective
method for gene inhibition with a high success rate [12].
Eukaryotes produce various types of small RNAs that
function in diverse pathways [3,13-15]. Since in some spe-
cies the active forms of small RNAs are often indistin-
guishable biochemically or functionally, they are
conventionally grouped into two classes based on their
origins and their biogenesis: microRNAs (miRNAs) and
small interfering RNAs (siRNAs). MiRNAs are generated
from the dsRNA region of the hairpin-shaped precursors,
whereas siRNAs are derived from long double-stranded
RNAs (dsRNAs) [16]. MiRNAs are transcribed as primary
miRNA transcripts (pri-miRNAs) which are then pro-
cessed within the nucleus by a complex consisting of
RNAse III enzyme Drosha and the double-stranded RNA-
binding protein DGCR 8 into pre-miRNAs. These are
exported from the nucleus into the cytoplasm by exportin-
5. In the cytoplasm the pre-miRNA enters the same path-
way as the above mentioned siRNA. At the end both
miRNAs and siRNAs bind to mRNA and induce mRNA
cleavage, translational repression, and cleavage-indepen-
dent mRNA decay [17]. While miRNAs predominantly
induce translational repression due to imperfect pairing to
their target mRNA, siRNAs often form a perfect duplex
with their target and therefore direct the cleavage of the
target mRNAs at the site of complementarity.
Figure 1 schematically summarizes the RNAi machin-
ery of the host cell.
Potential therapeutic targets for RNA interference
RNAi-based therapy for human cancer is one of the most
rapidly progressing applications for virally delivered
shRNA [18-20]. Theoretically, when using appropriately
designed siRNA, the RNAi machinery can be exploited to
silence almost any gene in the genome. Indeed, it has
already been reported that synthetic siRNAs are capable
of knocking down targets in various diseases in vivo
[21-23]. Experimentally tested, effective targets are genes
involved in cancer-associated cellular pathways, either
oncogenes, particularly fusion oncogenes due to their
unique link with certain tumor cells, or anti-apoptotic
genes. In addition, genes that play a role in tumor-host
interactions, such as factors involved in angiogenesis or
innate immunity, and those that mediate resistance to
chemo- or radiotherapy are targets for interference
[24,25]. For instance, cancer disease such as ovarian
cancer [26] and bone cancer [27] are currently being
investigated and successfully treated with siRNAs in vivo.
A further interesting therapy field is the area of
miRNA-caused malignancies. The direct effects of
miRNA, which are believed to regulate as many as one-
third of all human gene transcripts (or messenger
RNAs), are implicated in many human diseases. Using
gene therapy to manipulate miRNA levels represents an
attractive new approach for controlling gene expression
and identifying targeted and effective therapeutics [28].
An important role for miRNAs in cancer pathogenesis
has emerged over the last few years, and many reports
reveal numerous examples linking dysregulated expres-
sion of miRNAs to cancer [29,30]. Recent results
demonstrated that expression of a single miRNA in vivo
can reverse disease progression in a liver cancer model
[31]. This opened up a whole new replacement therapy
field for cancer treatment using RNAi.
Human pathogenic viruses are also excellent targets for
RNAi, because, as exogenous sequences, they are unique
in the host, which minimizes off-target side effects due to
the treatment. Here, the strategy is to target essential
viral genes to prevent viral proliferation. However, one
has to keep in mind that some viruses have acquired the
ability to counteract anti-viral RNAi. Examples of suc-
cessful RNAi approaches to combat human pathogenic
viruses include targeting Hepatitis B Virus (HBV) [32,33],
Human Papilloma Virus [34], Severe Acute Respiratory
Syndrome (SARS) Coronavirus [35], and Respiratory
Syncytial Virus (RSV) infections [36].
Other therapeutically relevant fields are metabolic
diseases, cardiac disorders, human neurodegenerative
diseases and inherited genetic diseases. A recently pub-
lished study showed successful siRNA targeting of
PCSK9, a member of the mammalian serine protein
convertase family, that typically functions in proteolytic
processing and maturation of secretory proteins and was
the first family member to be implicated in a dominantly
inherited form of hypercholesterolemia [37]. Targeting
PCSK9 with siRNA lowered plasma cholesterol and
hence offers an auspicious therapeutic approach to
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disease are also underway, using an RNA therapeutic
agent aimed at silencing one of the genes (c-myc) respon-
sible for causing arteries to reclose after stent insertion
(restenosis) [38]. Another study showed almost comple-
tely resolved liver fibrosis and prolonged survival in vivo
in rats following treatment with synthetic and modified
siRNAs. The efficacy highlighted a new therapeutic
potential for reversing human liver cirrhosis [39]. Table 1
provides a rough overview of current clinical trials for
siRNA therapeutics.
The first clinical trial conducted using siRNA was
aimed at age related macular degeneration (AMD) [40].
As early as 2004, the company Sirna presented the first
Figure 1 Schematic overview of the mechanism of RNA silencing in the host cell that leads to transcriptional silencing after retroviral
delivery of sh/miRNA. Retroviruses (or vectors) deliver therapeutic shRNA-expressing transgenes that integrate into the genome of the host cell
and lead to stable shRNA expression. Expressed shRNAs require the activity of endogenous Exportin 5 for nuclear export [129]. Several proteins are
recruited and form a dimer with Dicer which receives and subsequently cleaves the dsRNA generating duplex siRNAs with 2 nt 3’ overhangs. These
siRNAs activate the RNA-induced silencing complex (RISC) which unwinds the RNA and recruits only the guiding strand to target mRNA which is
subsequently cleaved and degraded. The figure is schematic, and the Dicer and RISC complexes can vary dependent on cellular process.
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pound AGN-745, formerly Sirna-027 - against AMD
[41]. The company OPOKO Health launched the first
ever siRNA Phase III trial in 2007 using Bevasiranib, a
first-in-class siRNA drug designed to silence the genes
producing Vascular Endothelial Growth Factor (VEGF),
believed to be largely responsible for vision loss in wet
AMD. Unfortunately in March 2009, the phase III trial
was terminated ahead of schedule due to a review by an
independent data committee, which found that although
the drug showed activity, the trial was unlikely to meet
its primary endpoint (OPOKO Health, Miami, Florida,
press release). One should keep in mind that the clinical
trials were performed with unmodified siRNAs and no
d o u b ts h o w e dg o o dr e s u l t s ,b u ta p p a r e n t l yn o tc o n v i n -
cing enough for human therapy.
Failure of this first clinical phase III study highlights
the need for second generation siRNA therapeutics, for
example shRNA-expression cassettes, as well as efficient
transfer vehicles for these cassettes.
Delivery of interfering RNA
In principal, there are many different ways to trigger
RNAi. Most of the proposed clinical applications of
RNAi incorporate chemically synthesized 21 nt siRNA
duplexes with 2 nt 3’ overhangs. This mode of adminis-
tration is transient, since intracellular concentrations of
the siRNAs are diluted during cell division. Further-
more, duplex siRNAs are negatively charged polymers
and therefore do not easily penetrate hydrophobic cellu-
lar membranes without assisting carriers. In addition,
unprotected and unmodified siRNAs are generally
rapidly degraded by serum RNases.
In contrast, intracellularly expressed short hairpin
RNAs mediate long-term knock-down of target tran-
scripts for as long as the shRNA is transcribed. Ther-
apy of chronic diseases, for example, requires exactly
this - long-term target gene down-regulation. An ideal
delivery vehicle should therefore facilitate endosomal/
lysosomal escape and, in the case of shRNA, the pay-
load must penetrate the nuclear membrane. Viruses
and vectors derived from them carry out precisely
these tasks and have therefore become a major delivery
system for shRNA.
RNAi in cells can be induced from intracellularly
expressed short hairpin RNAs either by shRNAs or syn-
thetic miRNAs [2,42,43]. The basic transcriptional unit
of shRNA is sense and antisense sequences connected
by a loop of unpaired nucleotides. MiRNA stem loops
are typically expressed as part of larger primary tran-
scripts (pri-miRNAs) [44]. Artificial miRNAs more natu-
rally resemble endogenous RNAi substrates and are
more amenable to Pol-II transcription and may seem to
be more attractive for therapies [44,45]. But to date
shRNA- and artificial miRNA-based strategies have been
compared with conflicting results [46-48] and it seems
that the choice is always dependent on the strategy and
the desired outcome and has to be figured out experi-
mentally [49].
Viral delivery of shRNA expression cassettes
Combining RNAi with viral gene therapy vectors is a
powerful approach in certain scenarios where spatiotem-
poral control over gene silencing is highly critical, and/
or where persistent suppression of a target is mandatory
for success. The design of viral RNAi vectors became
possible upon discovering that promoter-driven expres-
sion of short hairpin RNAs (shRNAs) induces the RNAi
machinery [50]. This strategy involves cloning an oligo-
nucleotide containing the siRNA sequence into plasmid
or viral vectors to endogenously express shRNA, which
is subsequently processed in the cytoplasm to siRNA.
Fortunately, shRNA expression cassettes are extremely
limited in size, meaning they can be packaged into even
Table 1 Current Clinical Trials for siRNA Therapeutics
Disease Mode of administration Status Company
Age-related macular degeneration (AMD) Topical Phase II Allergan
Respiratory syncytial virus (RSV) Local/direct Phase II Alnylam
Liver cancer (HCC and others) Systemic Phase I Alnylam
Hepatitis B Virus (HBV) Systemic Phase I Nucleonics
Solid tumors Systemic/local Phase I Calando Silence Therapeutics AG
Acute renal failure Systemic Phase I Quark Pharmaceuticals/Pfizer
Diabetic macular edema Topical Phase II Silence/Quark/Pfizer
Metastatic melanoma Local/direct Phase I Duke University
Pachyonychia congenita Topical Phase Ia/b Transderm
High cholesterol Systemic Phase I Tekmira Pharmaceuticals Corporation
Asthma Systemic Phase II ZaBeCor Pharmaceuticals
HIV Direct Phase I/II Benitec/City of Hope
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reviews existing viral vector systems.
Adenovirus vectors
Adenoviruses (AdV) belong to the family of Adenoviri-
dae, and adenoviral vectors are frequently used for
experimental gene therapy and 25% of clinical gene
therapy trials currently underway are using adenovirus
[51]. Adenoviruses are medium-sized, non-enveloped
viruses with a nucleocapsid and a linear dsDNA gen-
ome. They are able to replicate in the nucleus of mam-
malian cells but do not efficiently integrate into the
host’s genome. AdVs are able to package approximately
8-30 kb of foreign DNA. Several AdV features are
attractive for vector use, including infection of both
dividing and non-dividing cells, high levels of transgene
expression and the ability to grow to high titers in vitro.
There are 53 described serotypes in humans, and AdVs
are responsible for 5-10% of upper respiratory infections
in children and many infections in adults. Hence sero-
positivity to AdV is frequently observed, a drawback for
gene therapy using AdV. Entry of adenoviruses and
their vectors into cells involves two sets of interactions
between the virus and the host cell. First, the viral fiber
protein binds to the cell receptor, either CD46 for
group B human adenovirus serotypes or the coxsackie-
virus adenovirus receptor (CAR) for all other serotypes.
The initial binding is followed by a secondary interac-
tion, where the penton base protein interacts with an
integrin, resulting in entry of virions into the host cell
[52]. Adenoviral vectors exhibit no clear tissue tropism,
however the relevant surface receptors are often absent
in the tissue of interest (especially in tumor cells).
In connection with RNAi therapy the large packaging
capacity of a gutless adenovirus vector could be a problem
for small shRNA cassettes, since they might jeopardize
genetic vector stability [53]. A further disadvantage of
A d Vv e c t o r si st h ep r o b l e mo fr epeated administration,
which can trigger a strong immune response, potentially
limiting their effectiveness in certain therapeutic settings.
Additionally, the frequently described liver toxicity [54,55]
makes adenoviral vectors unsuitable, or at least to be
handled with care in human therapy.
Today, adenoviral vectors are a common delivery
method to introduce shRNA-expression cassettes into
target cells in vitro and are commercially available. Sev-
eral publications report the use of adenoviral vectors for
transducing RNAi-based therapies in vivo.T h ef i r s t
study employing an adenoviral vector for in vivo RNAi
was published in 2002 for an application in the central
nervous system [42]. These data validate the outstanding
promise of oncolytic adenoviral vectors for tumor-
restricted shRNA expression [56], although still with the
limitations mentioned above. Different reviews have
summarized adenoviral shRNA delivery in great detail
( e . g .[ 5 7 ] )a n dt h ei n t e r e s t e dr e a d e rs h o u l dr e f e rt o
them.
Adeno-associated virus vectors
Adeno-associated viral (AAV) vectors have also been
tested in clinical studies in multiple tissues [58]. AAV is
one of the smallest viruses and belongs to the genus
Dependovirus and the family Parvoviridae.I th a sa
small, single-stranded DNA genome (4.8 kb) and is
apathogenic in humans (at least according to current
knowledge). The genome contains only two genes,
which can be replaced with foreign ones, leaving only
the terminal ITRs to allow high-level expression of the
insert. However, the 5 kb packaging limit of AAV is still
sufficient to accommodate at least eight individual
shRNA expression cassettes [19,59]. The virus is replica-
tion-defective and until recently required adenovirus for
replication and production of vectors. New methods for
producing recombinant AAV using single adenoviral
genes have made adenoviral co-infection of AAV-produ-
cing cells dispensable [60]. Although wild-type AAV
preferentially integrates within a specific region of
human chromosome 19, recombinant AAV is engi-
neered to be inefficient in integration since it lacks the
AAV Rep protein [61,62].
In contrast to adenovirus, pseudotyping of AAV per-
mits entry retargeting, allowing delivery of the shRNA
cassette to specific cells or tissues [63]. Furthermore,
AAV-vectors show only low reactivity with cellular
immune responses.
To date, several reports have already described the
development of AAV vectors delivering and expressing
anti-tumor shRNAs in vitro as well as in small animal
models. One study exploited AAV expressing shRNAs
against Hec1 (highly expressed in cancer 1) [64].
Repeated intratumoral administration caused anti-pro-
liferative and pro-apoptotic effects in tumor cells.
Another recent study dealt with shRNA mediated
down-regulation of the androgen receptor (AR). Sys-
temic delivery of recombinant AAV vectors stably
expressing shRNA against the AR gene eliminated
prostate xenografts in nude mice [65]. Details and
further possible applications for AAV in shRNA deliv-
ery can be found elsewhere (e.g. [66,67]).
Both adenoviral (AdV) and adeno-associated virus
(AAV) vectors are non-integrating and therefore pose
only minimal risks of insertional mutagenesis. At the
same time, this may represent a negative aspect since
the genetic information is less stably conserved and may
be lost during repetitive cell division. So, although these
vectors transduce both dividing and non-dividing cells
allowing very efficient gene transfer, they are inadequate
for long-term gene replacement therapy.
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The use of gene delivery vectors based on retroviruses
was introduced in the early 1980 s by Mann et al. [68].
These single-stranded (ss)RNA viruses belong to the
family of Retroviridae and replicate through a double-
stranded DNA intermediate. They integrate their gen-
omes stably into the host cell DNA allowing long-term
expression of inserted therapeutic genes. The subfamily
of Orthoretrovirinae comprises different genii, for exam-
ple the simplest Gammaretroviruses (e.g. MLV) and the
more complex Lentiviruses (e.g. HIV). The viral genome
is approximately 10 kb, containing at least three genes:
gag (coding for core proteins), pol (coding for reverse
transcriptase) and env (coding for the viral envelope
protein). Complex retroviruses encode a number of
accessory proteins that are involved in regulating viral
replication or the host cell response to the virus. At
each end of the genome, long terminal repeats (LTRs)
contain promoter/enhancer regions and sequences
involved in integration. In addition there are sequences
required for packaging the viral RNA (psi Ψ
+).
Retroviral entry and genome integration do not
require viral protein synthesis; therefore all viral genes
in the vector genome can be replaced with foreign
sequences. Vector particles are produced by packaging
cell lines that provide the viral proteins in trans.T h e s e
cells release vector genomes packaged into infectious
particles that are free from contaminating helper virus
and replication-competent recombinant virus. Hence, no
viral proteins are produced after transduction, avoiding
inducing adverse effects or immune responses against
the vector particle, and preventing subsequent spread of
the vector.
When exiting the cell, retroviruses and their vectors
acquire cell-derived lipid bilayers containing inserted
glycoproteins (Env) by budding from the host cell mem-
brane. The Env protein mediates attachment and fusion
between the next host cell membrane and viral mem-
brane, which results in release of the viral capsid particle
containing the genetic material into the cytoplasm. This
plays a central role in targeting retroviral entry to target
cells, since Env interacts with a specific cellular protein
and accordingly determines viral tropism.
Altering the env gene or its product is one possible
way to manipulate the target cell range [69-72] and
increase the vector’s safety. The most successful
approach to enhancing safety for tumor therapy is engi-
neering protease-activated Env proteins. In this system,
viruses remain non-infectious until Env becomes acti-
vated via cleavage by a secreted or membrane-bound
protease that recognizes an engineered protease sub-
strate [73,74]. More detailed information can be found
elsewhere [75-78]. Selective infection of tumor cells
combined with transfer of anti-tumoral sh/mi/siRNAs is
an attractive strategy for cancer therapy, and is the
focus of current research. Several strategies have been
explored, and summaries can be found elsewhere [79].
The use of retroviral vectors for efficiently introducing
shRNA expression cassettes into target cells has been
exploited for many years now. Retroviruses were among
the first vectors used as transfer vehicles for hairpin-
RNA expressing plasmids. Brummelcamp et al. [50]
used retroviruses and highlighted the extreme specificity
of the RNAi concept, fanning interest in using RNAi for
therapeutic applications and cancer therapy. A number
of publications followed, using retroviral vectors based
on Murine Leukemia Virus (MLV) as transfer vehicles
for shRNA-expression cassettes. The most prominent
were the works of Paddison et al. [80] and Berns et al.
[81] both published in 2004. The groups generated
retrovirus-based shRNA expression libraries capable of
targeting around a third of all human genes. These
libraries showed promise in gene analysis and discovery
since they enabled large-scale genetic screens and
offered a tool for identifying genes involved in specific
biological processes.
Other work followed [48,82,83] applying retrovirally
delivered shRNA for high throughput screening. More
detailed views on pioneering experiments can be found
elsewhere (e.g. [18]), and retroviruses are still currently
being used as transfer vehicles for shRNA [84,85].
One recent study reported prolonged suppression of
productive HIV-1 infection in a T-cell line (Molt-4) by
a retrovirally (MLV) delivered shRNA targeting a
sequence located within the NF-B binding motif of
the HIV-1 promoter. HIV-1 expression in the shRNA
expressing CD4(+) T-cell line was suppressed for
1 year [86].
Lentivirus vectors
Lentiviruses (LV) constitute a subclass of retroviruses
and also carry two copies of a single-stranded RNA gen-
ome in an enveloped capsid. Among the different spe-
cies in the genus lentivirinae, the most prominent is the
Human Immunodeficiency Virus (HIV), as well as
others such as the Feline Immunodeficiency Virus (FIV)
or Simian Immunodeficiency Virus (SIV).
In contrast to the retroviral vectors above mentioned,
lentiviral vectors are capable of transducing dividing and
non-dividing cells (e.g. neurons), which makes them
preferred candidate vectors for nervous system applica-
tions. Lentiviral vectors can accommodate large (up to
7.5 kb) amounts of DNA [87], are less immunogenic
than adenoviral vectors and are mostly used for local
applications as well as for ex vivo gene therapy. They
are more complex than simple retroviruses, containing
additional six proteins, tat, rev, vpr, vpu, nef and vif.
Since the native viruses can cause fatal diseases in
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expression. Current packaging cells are usually trans-
fected with separate plasmids encoding for an env gene,
a transgene construct and a packaging construct supply-
ing the structural and regulatory genes in trans [88].
The most advanced and safest forms are the engineered
“self-inactivating” (SIN) vectors. Here, the U3 region of
the UTR is deleted, and a heterologous promoter (such
as CMV) ensures transcription of the entire vector
mRNA. This strategy excludes any risk of recreating
replication competent wildtype-like viruses by chance.
Just like the gamma-retroviruses, lentiviral vectors are
amenable to pseudotyping. For example, pseudotyping
of env with VSV-G broadens tropism and supports
uptake into otherwise refractory cells, such as human
hematopoietic or embryonic stem cells [89].
Lentiviruses are commonly used as vectors for the
transfer of shRNA-expression cassettes. Today, delivery
of shRNAs into target cells via lentiviral vectors is so
efficient that various companies offer this method for
in vitro experiments. During the past 10 years, several
adaptations and novel techniques have emerged to
improve (conditional) transgene expression, and the
assiduous scientist can choose between different well-
established systems for their experimental setup.
Examples for the use of lentiviral vectors as vector
systems for shRNA are innumerable, so here, we will
only touch on a few. In many cases, lentiviral vectors
have been employed successfully to regulate target genes
in the brain after local injection [42,90,91]. In an
upcoming clinical trial one application of RNAi will
involve ex vivo lentiviral vector delivery of an shRNA
expression cassette into hematopoietic stem cells
collected from patients infected with HIV. The trans-
duced cells must be re-infused into these patients for a
therapeutic benefit in vivo [92]. LV have also been used
t oc r e a t et r a n s g e n i ca n i m a l s ,b u to n ed r a w b a c ki st h e
fact that vectors become silenced after long-term culture
[93]. Different reviews give exhaustive surveys in great
detail, e.g. [94-97].
Baculovirus
The insect baculovirus is in its very early testing stages
as a possible vector for in vivo use and as vector for
shRNA [98]. Reports on baculovirus-delivered shRNA
comprise manageable amounts of publications. Vectors
based on baculovirus can transport large amounts of
genetic data leaving copious space for creative combina-
tion of gene therapy and silencing vectors [99]. Further-
more, baculovirus is unable to replicate and express
viral proteins in mammalian cells, making the virus a
safe gene therapy candidate now in its first developmen-
tal stages. Baculovirus-based shRNA expression is cur-
rently used to target different viral infections, for
example HCV replication [100,101] as well as Influenza
virus A and B [102]. However, the effects are transient,
since a major limitation of baculoviral transduction vec-
tors is the short duration of transgene expression. There
are ways to overcome this, for example by inserting
Epstein-Barr Virus sequences into the baculovirus vector
to improve long-term expression [103]. There is still a
long way to go before the promising results find their
way into human therapy trials.
Replicating Viruses
Effective gene-based therapies not only require efficient
delivery of therapeutic genes to targeted mammalian cells
but also continuous gene expression. Now, the realization
that conventional gene therapy approaches have yet to
deliver significant therapeutic benefit for cancer treat-
ment, combined with advances over the past 25 years,
has re-ignited interest in using replicating viruses. The
big advantage of replicating viruses in contrast to replica-
tion-defective vectors is that they are able to spread
through tumor tissue by viral propagation. In this setting,
each transduced/infected tumor cell becomes a virus-
producing cell, thereby sustaining further infection
beyond the initial inoculum. This idea led to a novel can-
cer therapy: oncolytic virotherapy. Recent advances in
molecular biology have allowed the design of several
genetically modified viruses, such as Adenovirus
[104,105] and Herpes Simplex Virus [106-108] that speci-
fically replicate in and kill tumor cells. Also Reovirus
[109,110], Poliovirus [111,112], Paramyxovirus [113],
Vaccinia Virus [114-117] and Vesticular Stomatitis Virus
[118] are being exploited. These viruses possess intrinsic
oncolytic activity since infection finally leads to host cell
death. In contrast, LV and MLV have no oncolytic activ-
ity, and shRNA-expression cassettes are used to fulfill
effector functions.
Conditionally replicating lentiviruses
Fully replicating lentiviruses such as HIV, due to their
calamitous risk to benefit ratios in healthy patients, are
not up for discussion as gene transfer vehicles. However,
in already infected HIV-1-positive patients gene transfer
using conditionally replicating lentiviral vectors are
under consideration [119,120]. A strategy based on
exploiting an HIV-based lentiviral vector carrying an
antisense sequence targeting HIV to treat HIV infection
has entered clinical trials. This trial is evaluating a con-
ditionally replicating HIV-1-derived vector pseudotyped
with VSV-G expressing an 937-base antisense gene
against the HIV envelope [120]. The novel idea is retain-
ing the full HIV LTRs in the vector, resulting in upregu-
lated expression of the antisense upon wildtype HIV
infection of the cell. The study showed improved cellu-
lar responses to HIV in four out of five subjects, and
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responses.
As opposed to the antisense-strategy used above,
another group is studying shRNA-expression cassettes
as transgenes in replicating HIV-1, using a doxycyclin-
dependent HIV-1 variant [119]. The virus replicated
conditionally in the presence of doxycyclin (dox) and
efficiently delivered anti-nef shRNAs to those cells sus-
ceptible to HIV-1 infection. Dox withdrawal generated
cells containing a silently integrated provirus with an
active shRNA expression cassette. Removal of nef-
sequences from the vector genome avoided vector self-
targeting but inhibited HIV-1 replication in transduced
cells in vitro.
The use of (conditionally) replicating lentiviral vectors
seems promising in the treatment of HIV-1 infections
using shRNA and may prove beneficial for this therapy
spectrum.
Replication competent MLV
Unique among the replicating viruses being developed
as oncolytic agents, retroviruses, in particular MLV-
based viruses, replicate without immediate lysis of host
cells and can maintain viral persistence through stable
integration.
Retroviruses have been studied extensively for almost
100 years and the work until now has culminated in the
first clinical trials [121] using replicating MLVs in vivo.
MLV exhibits tumor selectivity due to its inability to
infect quiescent cells and can achieve highly selective
a n ds t a b l eg e n et r a n s f e rt h r o u g h o u te n t i r es o l i dt u m o r s
in vivo at efficiencies of up to >99% even after initial
inoculation at MOIs as low as 0.01 [122]. One obstacle
to overcome in tumor therapy using replication compe-
tent retroviruses is the restricted size for inserted trans-
g e n e s .T h es i z eo ft h eM L Vg e n o m ei sl i m i t e dt o
roughly 11 kb and viral genes cannot be replaced by
transgenes.
One possibility to overcome this restriction is engi-
neering MLVs in a semi-replicative setting. The idea is
to split the viral genome onto two transcomplementing
vectors, each carrying the genetic information for either
gag/pol or env and/or a transgene. Only together - not
alone - these vectors contain the genetic material neces-
sary for replication and vector production upon cell
transfection. We and others developed this idea
[71,123,124], where the gag/pol and env genes are split
between two viral genomes. The duo allows co-propaga-
tion of two different transgenes, which offers both a
back-up therapeutic opportunity, should the effect of
the first gene product wane due to developing drug
resistance, and a means for vector replication shut off, if
the transgene is a suicide gene. The split genomes also
enhance the capacity for inserting a therapeutic gene.
We constructed split viral genomes and used fluorescent
proteins to visually monitor viral replication of the
resulting SRRVs [71].
Replication competent viruses containing the complete
genome can also be used to carry transgenes. In 2001,
Logg and Kasahara [125] conducted studies testing the
insertion capacity of replicating viruses and found that
MLVs containing inserts of 1.15 to 1.30 kb replicated
with only slightly attenuated kinetics compared to wild-
type and efficiently spread transgenes after in vivo
administration.
Many reports describe replicating MLVs for gene ther-
apy using inserted suicide genes [126]. We pioneered
replicating MLVs as transfer vehicles for shRNAs to
amplify shRNA delivery [127]. Our replicating MLV
constructs express shRNA under the control of an RNA
pol III promoter [50,128]. Inserting the cassette did not
interfere significantly with viral fitness, and vectors were
genetically stable and functional in silencing target gene
expression. Our results show that replicating MLVs are
excellent tools for efficient delivery and expression of
shRNAs, have great potential for functional genomics,
and might be suitable for in vivo cancer gene therapy, if
combined with efficient entry targeting. We are cur-
rently focusing on in vivo studies using these viruses
and look forward to promising results.
Conclusions
RNAi technology has become a powerful tool and key
method for gene therapy in the scientist’sh a n d s .
A l t h o u g ht h ee f f e c t i v e n e s so fR N A ii su n d o u b t e d ,t h e r e
are still limitations to exploiting the technology properly
due to inefficient delivery and distribution of the
shRNA-cassettes into the target cells. Focusing on viral
delivery of shRNA, we highlighted that viruses and vec-
tors derived from them are excellent candidates to deli-
ver shRNA into the desired tissue or cells. We discussed
different methods for viral delivery of shRNA expression
cassettes using conventional methods and revealed pro-
mising new strategies utilizing replicating retroviruses.
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